AI Article Synopsis
- Diabetes significantly increases the risk of atherosclerotic cardiovascular disease (ASCVD), leading to serious health issues for those with diabetes.
- Effective prevention of cardiovascular complications includes managing dyslipidemia and maintaining good blood sugar control.
- New lipid-lowering therapies, especially PCSK9 inhibitors like alirocumab, show promise in helping diabetic patients achieve their cholesterol targets when traditional therapies alone are insufficient.
Article Abstract
Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of <70 mg/dL or target non-high-density lipoprotein goal of <100 mg/dL. Lipid-lowering therapies (LLTs), such as statins and ezetimibe, are the cornerstone for plasma LDL-C lowering; however, individuals with diabetes are often unable to achieve target lipid goals with these therapies alone and frequently require additional treatments. A new class of LLTs, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, provides a novel approach to lowering lipids in persons with high CV risk, such as those with diabetes. The clinical data presented in this review indicate the potential benefits of alirocumab in patients with diabetes and its value as a treatment option in patients with diabetic dyslipidemia with no significant safety concerns.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756838 | PMC |
| http://dx.doi.org/10.2147/DMSO.S167375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re-thinking the link between exposure to mercury and blood pressure.
Arch Toxicol
January 2025
Chemical and Environmental Toxicology Program, Department of Biology, University of Ottawa, 30 Marie Curie, Ottawa, ON, K1N 6N5, Canada.
Hypertension or high blood pressure (BP) is a prevalent and manageable chronic condition which is a significant contributor to the total global disease burden. Environmental chemicals, including mercury (Hg), may contribute to hypertension onset and development. Hg is a global health concern, listed by the World Health Organization (WHO) as a top ten chemical of public health concern.
View Article and Find Full Text PDFEffect of genetic and vascular risk factors on rates of cognitive decline in early-onset and late-onset Alzheimer's disease.
J Alzheimers Dis
January 2025
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Although previous studies have shown that cognitive decline in Alzheimer's disease (AD) is associated with various risk factors, they primarily focused on late-onset AD (LOAD).
Objective: We aim to evaluate the differential impact of risk factors on the cognitive decline between early-onset AD (EOAD, onset < 65 years) and LOAD (onset 65 years) and explore the longitudinal effect of Apolipoprotein E allele 4 ( ε4) on cortical atrophy in both cohorts.
Methods: Using data from 212 EOAD and 1101 LOAD participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), we conducted multivariable mixed-effect models to evaluate the impact of ε4, education, hypertension, diabetes, dyslipidemia, and body mass index on cognitive performance.
Reduction in Remnant Cholesterol in Obese Individuals After Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomy.
Nutrients
January 2025
Department of Research, Innlandet Hospital Trust, P.O. Box 104, N-2381 Brumunddal, Norway.
The effectiveness of bariatric surgery in reducing remnant cholesterol (RC) levels, particularly when obesity is accompanied by elevated glycated hemoglobin (HbA1c), is insufficiently investigated. In this study, we aimed to examine the impacts of two common bariatric procedures, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), as regards their effects on RC and HbA1c levels. Adult morbidly obese subjects were included and assigned to receive either RYGB or SG.
View Article and Find Full Text PDFEarly life factors and later metabolic syndrome in European children and adolescents.
Nutr Metab Cardiovasc Dis
November 2024
Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Background And Aims: Early life factors have been suggested to be associated with later cardiometabolic risk in children, adolescents and adults. Our study aimed to investigate the associations between early life factors and metabolic syndrome (MetS) in children and adolescents.
Methods And Results: Our analysis sample comprised of 8852 children aged 2-9 years at baseline that participated in up to three examination waves of the pan-European IDEFICS/I.
Statins for vascular dementia: A hype or hope.
Neuroscience
December 2024
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt.
Article Synopsis
- Vascular dementia (VaD) is the second most common type of dementia after Alzheimer’s disease, characterized by cognitive impairment and memory loss, often linked to cerebral amyloid angiopathy (CAA).
- Early diagnosis and the use of anti-inflammatory treatments can potentially prevent the development of VaD, but there are currently no effective drugs available specifically for its management.
- Statins, commonly used for lowering cholesterol, may show promise in treating VaD and improving cognitive function, but the exact mechanisms of their effectiveness are still not well understood.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!